Geczy C L, Geczy A F, De Weck A L
J Immunol. 1976 Nov;117(5 Pt.2):1824-31.
An antiserum, (anti-lymphokine globulin, ALyG) directed against highly purified products of activated lymphocytes, inhibits the proliferation of responding cells in guinea pig mixed leukocyte cultures ((MLC). This serum recognizes three newly synthesized lymphocyte products (one of them being migration inhibition factor (MIF) which are involved in the mediation of delayed hypersensitivity reactions in vivo. Since ALyG does not appear to contain cytotoxic antibodies against guinea pig lymphocyte antigens and its inhibitory activity cannot be removed by absorption with lymphoid cells it seems likely that the inhibition of MLC reactivity is not mediated by the lysis of stimulator or responder cells and its target is not the lymphocyte per se but possibly some factor elaborated during MLC response. By contrast, antisera with specificity for histocompatibility (H) antigens can inhibit the MLC when the appropriate H antigens are present on the responding and/or stimulating cell population. However, this inhibitory of the antisera can be effectively absorbed with lymphoid cells bearing the appropriate H antigens. The addition of ALyG even 48 hr after the initiation of culture results in a marked inhibition of MLC reactivity. This finding is consistent with the elaboration of a mitogenic factor or signal during the first 48 hr of culture and the delivery of this signal to the responding cell population. Thus, ALyG does not appear to interfere with the synthesis of this factor but must be present after its release in order to block responder cell proliferation. Furthermore, the stimulatory effect of this MLC mitogenic factor, but not of PPD-induced mitogenic factor on "third party" cells can be completely inhibited when the cells are cultured in the presence of ALyG. These findings suggest that the MLC-mitogenic factor in this system is identical to or cross-reactive with one or both of the newly synthesized molecules recognized by the ALyG.
一种抗血清(抗淋巴细胞球蛋白,ALyG),针对活化淋巴细胞的高度纯化产物,可抑制豚鼠混合淋巴细胞培养物(MLC)中反应细胞的增殖。这种血清识别三种新合成的淋巴细胞产物(其中一种是迁移抑制因子(MIF)),它们参与体内迟发性超敏反应的介导。由于ALyG似乎不含有针对豚鼠淋巴细胞抗原的细胞毒性抗体,且其抑制活性不能通过与淋巴细胞吸收而去除,因此MLC反应性的抑制似乎不是由刺激细胞或反应细胞的裂解介导的,其靶标不是淋巴细胞本身,而是可能在MLC反应过程中产生的某些因子。相比之下,对组织相容性(H)抗原有特异性的抗血清,当反应和/或刺激细胞群体上存在适当的H抗原时,可抑制MLC。然而,这种抗血清的抑制作用可被携带适当H抗原的淋巴细胞有效吸收。即使在培养开始48小时后加入ALyG,也会导致MLC反应性的显著抑制。这一发现与培养的前48小时内产生促有丝分裂因子或信号,并将该信号传递给反应细胞群体一致。因此,ALyG似乎不干扰该因子的合成,但必须在其释放后存在才能阻断反应细胞的增殖。此外,当细胞在ALyG存在下培养时,这种MLC促有丝分裂因子对“第三方”细胞的刺激作用,而不是PPD诱导的促有丝分裂因子的刺激作用,可被完全抑制。这些发现表明,该系统中的MLC促有丝分裂因子与ALyG识别的一种或两种新合成分子相同或交叉反应。